OPG, RANK and RANK ligand expression in thyroid lesions
暂无分享,去创建一个
M. Heymann | D. Heymann | J. Paineau | S. Battaglia | B. L. Goff | A. Riet
[1] D. Heymann,et al. Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. , 2007, Oncology reports.
[2] J. Golledge,et al. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. , 2007, Cardiovascular research.
[3] B. Pitard,et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.
[4] S. Vukicevic,et al. Thyroid‐Stimulating Hormone Restores Bone Volume, Microarchitecture, and Strength in Aged Ovariectomized Rats* , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[5] D. Heymann,et al. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases , 2007, Cellular and Molecular Life Sciences.
[6] M. Mussap,et al. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study. , 2007, Metabolism: clinical and experimental.
[7] A. Boyde,et al. Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. , 2007, Molecular endocrinology.
[8] B. Le Goff,et al. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. , 2007, Bone.
[9] B. Le Goff,et al. Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B , 2007, The Journal of pathology.
[10] M. Padrines,et al. Key roles of the OPG–RANK–RANKL system in bone oncology , 2007, Expert review of anticancer therapy.
[11] Y. Hattori,et al. Correlation between Serum Osteoprotegerin and Biomarkers of Bone Metabolism during Anti-Thyroid Treatment in Patients with Graves’ Disease , 2006, Hormone Research in Paediatrics.
[12] H. Stettner,et al. Receptor activator of nuclear factor κB ligand and osteoprotegerin in men with thyroid cancer , 2006, European journal of clinical investigation.
[13] L. Pham,et al. Nuclear Localization in the Biology of the CD40 Receptor in Normal and Neoplastic Human B Lymphocytes* , 2006, Journal of Biological Chemistry.
[14] S. M. Sims,et al. Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.
[15] Y. Kadono,et al. Osteoimmunology: interplay between the immune system and bone metabolism. , 2006, Annual review of immunology.
[16] C. Ahn,et al. Clinical features of bone metastases resulting from thyroid cancer: a review of 28 patients over a 20-year period. , 2005, Endocrine journal.
[17] J. Patsch,et al. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. , 2005, The Journal of clinical endocrinology and metabolism.
[18] M. Inaba,et al. Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. , 2005, European journal of endocrinology.
[19] Z. Lin-shuang,et al. Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients , 2005, Journal of endocrinological investigation.
[20] S. Théoleyre,et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.
[21] B. Biondi,et al. Recombinant Human TSH Modulates In Vivo C‐Telopeptides of Type‐1 Collagen and Bone Alkaline Phosphatase, but Not Osteoprotegerin Production in Postmenopausal Women Monitored for Differentiated Thyroid Carcinoma , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[22] K. Chihara,et al. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL–RANK interaction , 2004, Journal of cellular physiology.
[23] B. Biondi,et al. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. , 2004, Bone.
[24] C. Wiedermann,et al. Expression and function of RANK in human monocyte chemotaxis. , 2004, Arthritis and rheumatism.
[25] S. Spitzer,et al. Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25D3) Inversely Regulate OPG Gene Expression in Dependence of the Osteoblastic Phenotype , 2004, Calcified Tissue International.
[26] M. Zaidi,et al. TSH Is a Negative Regulator of Skeletal Remodeling , 2003, Cell.
[27] J. Goldman,et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. , 2003, Blood.
[28] Brian D. Strahl,et al. A nucleosomal function for IκB kinase-α in NF-κB-dependent gene expression , 2003, Nature.
[29] P. Pietschmann,et al. Serum levels of osteoprotegerin increase with age in a healthy adult population. , 2003, Bone.
[30] Raoul Rooman,et al. Dexamethasone differentially inhibits thyroxine- or growth hormone-induced body and organ growth of Snell dwarf mice. , 2003, Endocrinology.
[31] L. Mosekilde,et al. Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. , 2003, The Journal of clinical endocrinology and metabolism.
[32] A. Wells,et al. Signalling shortcuts: cell-surface receptors in the nucleus? , 2002, Nature Reviews Molecular Cell Biology.
[33] K. Nakao,et al. A novel interaction between thyroid hormones and 1,25(OH)(2)D(3) in osteoclast formation. , 2002, Biochemical and biophysical research communications.
[34] K. Makino,et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.
[35] P. Hersey,et al. Differential Localization and Regulation of Death and Decoy Receptors for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Human Melanoma Cells1 , 2000, The Journal of Immunology.
[36] D. Forrest,et al. Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. , 1999, Genes & development.
[37] W. Min,et al. The N-terminal domains target TNF receptor-associated factor-2 to the nucleus and display transcriptional regulatory activity. , 1998, Journal of immunology.
[38] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[39] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[40] H. Kawaguchi,et al. Comparison of the effects of 3,5,3′‐triiodothyroacetic acid and triiodothyronine on bone resorption in cultured fetal rat long bones and neonatal mouse calvariae , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[41] M. Hansen,et al. Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[42] D. Heymann,et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. , 2003, The American journal of pathology.
[43] L. Hofbauer,et al. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland , 2002, Journal of cellular biochemistry.